Advanced

A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus

Stockeld, Dag; Tennvall, Jan LU ; Wagenius, Gunnar; Albertsson, Maria LU ; Backman, Lars; Brodin, Ola; Cwikiel, Magdalena LU ; Granstrom, Lars; Gustafsson, Gunnar and Gustavsson, Sven, et al. (2001) In Acta Oncologica 40(5). p.566-573
Abstract
This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion... (More)
This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion of patients (13/23 [57%] before changes of treatment compared with 30/36 [83%] after changes). Treatment-related mortality was 3.75% (3 patients, associated with leucopenic septicemia after chemotherapy). Fifty-four patients were resected. No per- or postoperative mortality was encountered. The complete response (pathological CR) rate in operated patients was 46% (27/59 patients) after chemoradiation. In the whole series the CR rate (including clinical CR for non-resected patients) was 44%. With a minimum follow-up of 37 months, the 3-year survival for the whole group was 31% compared with 57% for the CR patients. Total 5-year survival thus far (July 1999) is 26%. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
40
issue
5
pages
566 - 573
publisher
Taylor & Francis
external identifiers
  • pmid:11669327
  • scopus:0034789236
ISSN
1651-226X
DOI
language
English
LU publication?
yes
id
a163f61a-ba3e-433e-99f3-e1adf6dd56e5 (old id 1121799)
date added to LUP
2008-07-15 10:41:46
date last changed
2018-05-29 10:22:00
@article{a163f61a-ba3e-433e-99f3-e1adf6dd56e5,
  abstract     = {This multicenter study describes the development of a chemoradiation protocol for the treatment of non-metastatic squamous cell carcinoma of the esophagus. Eighty patients were treated with three courses of chemotherapy (cisplatinum and 5-fluorouracil) with concomitant radiotherapy (40 Gy) during the last two courses of chemotherapy. Esophagectomy was performed, when feasible. If no operation was performed, patients were planned to receive a target dose of 64 Gy. Toxicity was mainly attributable to hematological impairment and led to two adjustments of the treatment protocol (addition of filgrastim and lowering of the 5-fluorouracil dose). These changes made it possible to administer the planned treatment in a gradually higher proportion of patients (13/23 [57%] before changes of treatment compared with 30/36 [83%] after changes). Treatment-related mortality was 3.75% (3 patients, associated with leucopenic septicemia after chemotherapy). Fifty-four patients were resected. No per- or postoperative mortality was encountered. The complete response (pathological CR) rate in operated patients was 46% (27/59 patients) after chemoradiation. In the whole series the CR rate (including clinical CR for non-resected patients) was 44%. With a minimum follow-up of 37 months, the 3-year survival for the whole group was 31% compared with 57% for the CR patients. Total 5-year survival thus far (July 1999) is 26%.},
  author       = {Stockeld, Dag and Tennvall, Jan and Wagenius, Gunnar and Albertsson, Maria and Backman, Lars and Brodin, Ola and Cwikiel, Magdalena and Granstrom, Lars and Gustafsson, Gunnar and Gustavsson, Sven and Hambraeus, Göran and Lewensohn, Rolf and Sjöstedt, Svante and Strander, Hans and Aberg, Bengt and Fagerberg, Jan},
  issn         = {1651-226X},
  language     = {eng},
  number       = {5},
  pages        = {566--573},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus},
  url          = {http://dx.doi.org/},
  volume       = {40},
  year         = {2001},
}